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Introduction: There has been a significant increase in the use of testosterone in aging men, but little investigation
into its impact on men with Alzheimer’s disease (AD). The findings of the few studies that have been done are
inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and
neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD.
Methods: The sample, which was drawn from the Texas Alzheimer’s Research Care Consortium Longitudinal
Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was
gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and
the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group
(TT ≥2.6 ng/ml; n = 43).
Results: TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity.
The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56),
delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group.
Health status and apolipoprotein E ε4 status were not significant factors.
Conclusions: The findings of the present study have implications for the use of testosterone replacement
therapy in men with AD or the prodromal stage of the disease.Introduction
The majority of individuals with Alzheimer’s disease
(AD) experience one or more neuropsychiatric symp-
toms (NPS) [1] during the course of the disease. The
presence of these symptoms has a significant impact on
quality of life, both for the patients [2] and for their
caregivers [3,4], and increases the risk of nursing home
placement and death [5]. The occurrence of these symp-
toms in AD is affected by a number of factors, including
sex [6], previous psychiatric history [7], stage of the dis-
ease [8] and situational factors [9]. In our prior work, we
began to identify potential blood-based biomarkers of
NPS in AD [10,11]. Sex-specific patterns of biomarkers* Correspondence: james.hall@unthsc.edu
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unless otherwise stated.[10] emerged, with dysregulation of inflammatory bio-
markers being related to the occurrence of NPS in
women and elevated total cholesterol related to NPS in
men [10,11]. Different patterns of inflammatory biomarkers
were found for female apolipoprotein E ε4 (APOE ε4)
carriers and noncarriers, whereas APOE ε4 status was
not a factor for men [11]. These sex differences suggest
that sex hormones may be related to the occurrence of
NPS in AD.
A number of studies have reported a link between low
testosterone levels and the risk for developing AD [12-14].
Testosterone has been proposed to be neuroprotective by
affecting amyloid-β protein metabolism and oxidative
stress [15]. Low levels of testosterone have been related to
poorer sense of psychological well-being [16] and subsyn-
dromal levels of depression and anxiety in healthy older
men [17]. High levels of testosterone may have a positive
effect but also may be detrimental [18]. Studies of aggres-
sion in men have found a relationship between high levelsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and Luttrell [21] reviewed studies of neuroimaging related
to emotional and aggressive behaviors and found that the
prefrontal, temporal and subcortical substructures of the
hypothalamus and amygdala were involved. Batrinos [19],
in his discussion of testosterone and aggressive behavior,
described the subcortical structures of the hypothalamus
and the amygdala as the places where aggression and
emotions are “born” and the prefrontal cognitive structures
as the places where they are “perceived and controlled.”
High levels of testosterone are seen as downregulating the
interaction between the cognitive and emotional systems
and reducing the effectiveness of cognitive controls [22].
AD has a significant impact on those areas of the brain that
are involved in the expression and control of emotional
behavior. The possible link between testosterone and
aggression and other NPS in AD has not been exten-
sively investigated, and the results of the limited re-
search that has been done tends to be contradictory.
Orengo et al. [23] found a relationship between testoster-
one levels and aggression in elderly men with dementia.
There was no relationship between testosterone and total
score on the Neuropsychiatric Inventory (NPI), a measure
of the occurrence and severity of NPS. Xing et al. [24]
found no relationship between levels of sex hormones, in-
cluding testosterone, and NPS in a sample of men with
vascular dementia, although sex hormones were associ-
ated with NPS among women. In a study of the impact of
APOE ε4 status on the relationship between sex hormones
and NPS in AD [25], sex-specific effects of testosterone
were found regarding the occurrence of agitation and/or
aggression, but again only for women, not for men.
In the present study, we sought to clarify the link
between testosterone and NPS in AD by investigating
the relationship of total testosterone (TT) with the occur-
rence of NPS in a sample of elderly men with AD.
Methods
Participants
The sample was drawn from individuals enrolled in the
Longitudinal Research Cohort of the Texas Alzheimer’s
Research Care Consortium (TARCC) who had a complete
serum biomarker panel and a completed NPI interview.
The TARCC is a longitudinal multisite cohort of patients
with AD and normal controls in which each participant
undergoes an annual evaluation that includes a medical
examination, an interview, neuropsychological testing and
a blood draw. Patients with AD met consensus-based
diagnostic criteria for probable AD based on National
Institute of Neurological and Communicative Disorders
and Stroke and Alzheimer’s Disease and Related Disorders
Association guidelines [26]. As we investigated the role of
testosterone in elderly men, only men were included in
the sample. The final sample consisted of 87 men whomet the diagnostic criteria for AD. The mean age of the
sample was 75.67 years (standard deviation (SD) = 8.03);
the average education level was 13.44 years (SD = 4.32);
the mean Mini Mental State Examination (MMSE) score
was 20.07 (SD = 6.79); the mean Clinical Dementia Rating
(CDR) scale score was 1.10 (SD = 0.73); and the mean
CDR Sum of Boxes score was 6.62 (SD = 4.47). The total
years of education completed was determined by patient
self-report. APOE ε4 carriers made up 54% of the partici-
pants, and 96% of the participants were non-Hispanic
Caucasians. Institutional review board approval was
obtained at each TARCC site (see Acknowledgements
for details), and written informed consent was obtained
from all participants and/or their caregivers.
As part of the TARCC evaluation, individuals familiar
with the behavior of the participants (that is, caregivers
and/or family members) who accompanied the participants
to the evaluation were administered the NPI Questionnaire,
which is a brief, valid and reliable instrument used in the
assessment of NPS [27]. When more than one caregiver
attended the evaluation, the NPI was conducted with the
individual with greatest knowledge of the participant’s
behavior. Consistent with our previous research [10,11],
the analyses in this study were focused on the presence or
absence of a behavior rather than on the more subjective
estimate of perceived severity. In the analyses, the occur-
rence of NPS and the total number of symptoms reported,
as well as of each of the specific symptoms, served as the
primary outcomes.
Biomarkers
The TARCC research platform uses the Myriad RBM
Human Multi-Analyte Profile multiplexed immunoassay
(HumanMAP; Myriad RBM, Austin, Texas, USA) to
analyze blood-based biomarkers.
Assays
Nonfasting samples were drawn with 21- to 23-gauge
needles into 10-ml serum-separating (tiger top) vacutai-
ner tubes at the time of interview. Samples were allowed
to clot at room temperature for 30 minutes in a vertical pos-
ition before being centrifuged at 1,300 × g for 10 minutes.
Next, 1-ml aliquots were pipetted into polypropylene cryo-
vial tubes and placed in −20°C (non-frost-free) or −80°C
freezers until shipment to the TARCC Biobank for long-
term storage at −80°C. Total processing time (from needle-
stick to freezer) was 2 hours or less. All samples obtained
from the present project were shipped on dry ice to
Myriad RBM for assay on the Luminex-based Human-
MAP 1.0 platform (Luminex, Austin, Texas, USA).
Data analysis
TT was determined for each participant. The participants
were grouped into hypogonadal or borderline/normal
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[28,29] definition of hypogonadism as TT ≤2.5 ng/ml.
Participants were grouped into either the low-testosterone
group (Low T) (TT ≤2.5 ng/ml) or the borderline/normal
testosterone group (Normal T) (TT ≥2.6 ng/ml). The total
number of participants with TT ≤2.5 ng/ml was 44, and
43 participants had TT ≥2.6 ng/ml and thus were in
the Normal T group. APOE ε4 status (carriers versus
noncarriers) was also analyzed. Data were analyzed using
product-moment correlations, t-tests and multivariate
analysis of variance. The 0.05 level of significance was
applied to the data.
Results
Table 1 shows that the sample was composed of older
men with a relatively high level of education in the mild
stage of disease progression. When divided based on tes-
tosterone level, the two groups did not differ with regard
to age, years of education or level of cognitive impair-
ment (as assessed by the MMSE and CDR-Global score).
Disease progression as assessed by the CDR Sum of
Boxes did not differ between the two groups. There was
no difference between the groups with regard to per-
centage of APOE ε4 carriers. The number of total NPS
reported for each group was not significantly different.
Analysis of the two groups regarding health history
showed no significant differences in the percentage of
individuals with hypertension, hyperlipidemia, diabetes or
obesity. Product-moment correlations (Table 2) revealed
significant correlations (P < 0.05) between TTand the total
number of NPS reported, along with the symptoms of hal-
lucinations, delusions, agitation, irritability and motor
activity. Multivariate analysis of variance revealed no
significant main effect for TT.Table 1 Characteristics of the samplea
Total sample Low testos
(N = 87) (n = 44)
Age, yr 75.67 (8.033) 77.24 (7.845
Education level, yr 13.44 (4.324) 14.14 (3.771
MMSE score 20.07 (6.789) 20.45 (5.584
CDR-Global score 1.10 (.727) 1.08 (.698)
CDR-SOB score 6.62 (4.474) 6.38 (4.019)
NPI total 4.15 (2.888) 3.619 (2.408
Testosterone, ng/ml 2.49 (1.046) 2.11 (.804)





aAPOE ε4, Apolipoprotein E ε4; CDR, Clinical Dementia Rating; MMSE, Mini Mental S
presented are mean (standard deviation) or percent values. *Significant P < 0.05.Multivariate analysis of variance was carried out to as-
sess the differences between the two testosterone levels
on the specific symptom domains of the NPI. The ef-
fect of APOE ε4 status was also assessed. The analysis
revealed significant differences between the testosterone-
level groups on the reported occurrence of hallucinations
(F(1, 86) = 4.339 (P = 0.04)), symptoms of irritability
(F(1, 86) = 5.747, P = 0.022)) and symptoms of motor
activity (F(1, 86) = 5.708, P = 0.019)). No significant
differences between the two groups were found for
any of the other symptoms assessed by using the NPI.
APOE ε4 status was not a significant factor, and no
significant difference was found between the groups
for frequency of APOE ε4 carriers versus noncarriers.
Odds ratios (ORs) were calculated for the NPI symp-
toms (Table 3) by comparing the two groups based on tes-
tosterone level. The likelihood of having hallucinations
reported was 13 times greater for the Normal T group.
Hallucinations were reported infrequently overall, with 1
of the 44 Low T individuals reporting hallucinations and
10 of the 43 Normal T individuals reporting them.
Delusions were almost four times (OR = 3.87, 95%
confidence interval (CI): 1.137 to 13.177; P = 0.022)
more likely in the Normal T group, with twelve individ-
uals reporting delusions compared with four in the
Low T group. Irritability, which on the NPI is related
to being “cranky, impatient or having difficulties deal-
ing with delays or waiting,” was a relatively frequently
reported symptom, with 20 members of the Low T group
and 30 of the Normal T group being described as having
irritability. Irritability was reported nearly three times
(OR = 2.77; 95% CI: 1.148 to 6.681, P = 0.018) more
often in the Normal T group than in the Low T group.
Aberrant motor behavior, described on the NPI asterone Borderline/Normal testosterone P-value
(n = 43)
) 74.14 (8.008) 0.075
) 12.74 (4.746) 0.137
) 19.70 (7.839) 0.611
1.12 (0.762) 0.836
6.86 (4.914) 0.624







tate Examination; NPI, Neuropsychiatric Inventory; SOB, Sum of Boxes. Data
Table 2 Correlations between total testosterone and
neuropsychiatric symptomsa
NPI symptoms Total testosterone (r-value) P-value













aNPI, Neuropsychiatric Inventory. r-values represent product-moment
correlation. *Significant at P < 0.05.
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ling buttons, or doing things repeatedly,” was reported
almost three times (OR = 2.942, 95% CI: 1.104 to 7.841,
P = 0.024) as often for the Normal T group, with eight
individuals in the Low T group and seventeen in the
Normal T group having symptoms related to motor
disturbances. The ORs for the remaining NPS were
not significant.
Discussion
There has been a significant increase in the use of tes-
tosterone replacement therapy (TRT) for older menTable 3 Odds ratios for occurrence of neuropsychiatric
symptoms among borderline/normal compared with
low-testosterone groupsa
NPS Odds ratio 95% confidence
interval
P-value
Hallucinations 13.03 1.588 to 106.954 0.003*
Aberrant motor behavior 2.94 1.191 to 7.841 0.024*
Irritability 2.77 1.148 to 6.681 0.019*
Anxiety 1.24 0.552 to 2.986 0.374
Disinhibition 1.82 0.779 to 4.271 0.119
Delusions 3.87 1.137 to 13.177 0.022*
Agitation 1.83 0.779 to 4.271 0.119
Depression 1.26 0.532 to 2.986 0.380
Apathy 1.17 0.493 to 2.767 0.447
Elation 1.03 0.275 to 3.833 0.616
Appetite 1.52 0.645 to 3.585 0.229
Nighttime 1.16 0.496 to 2.703 0.451
aNPS, Neuropsychiatric symptoms. *Significant at P < 0.05.[30], without clear evidence of the impact of testosterone
on behavior in diseases where cognitive functioning has
been compromised. The presently reported research
shows a link between testosterone levels and the occur-
rence of specific NPS in elderly men with AD. This rela-
tionship is with symptoms that could be described as
“active,” or “acting out” or in the terms used to describe
symptoms of schizophrenia “positive” symptoms. No re-
lationship was found for depression, apathy or distur-
bances of sleep or appetite. Individuals with borderline
to normal testosterone levels were significantly more
likely to have hallucinations, delusions, aberrant motor
symptoms and irritability than those with low testoster-
one. It could be argued that those with low testosterone
would be less likely to have the energy to engage in act-
ing out. Our sample represented a relatively healthy
community-dwelling population, and there was no
difference on any of the health measures. Frailty and
loss of vigor that may accompany low testosterone
cannot account for the differences in hallucinations
and delusions.
A number of mechanisms have been proposed to ex-
plain testosterone’s neuroprotective effects related to the
risk of developing AD [31], but there is a lack of explana-
tory paradigms to explain our findings. The pathological
changes that occur in AD, specifically degeneration in the
hippocampus, may make the brain more susceptible to
the effects of even normal levels of testosterone. The
hippocampus has connections with the hypothalamus and
amygdala, structures that are involved in emotional
reactivity and the inhibition of emotional behavior
[32] through projections to autonomic and endocrine
emotion generation systems [33]. The salience net-
work, which has connections to these structures, is
said to be involved in reactivity to emotional stimuli.
Balthazar et al. [34] argued that changes in salience net-
work connectivity are related to hyperactivity symptoms
in AD. In essence, the individual becomes more reactive
to affective stimuli and less discerning. The structures
involved in this process have a high density of sex hor-
mone receptor, which are responsive to testosterone
[35]. The salience network may also be involved in the
formation of delusions. In research on patients with
psychosis, the encoding of usually irrelevant stimuli
versus relevant stimuli is affected [36] and the irrelevant
stimuli take on greater salience. Along with affecting re-
activity, testosterone decreases subcortical–cortical func-
tional connectivity [37], reducing the inhibition of emotions
by higher cortical structures. Testosterone reduces the regu-
latory control of the orbitofrontal cortex over the amygdala.
Mega et al. [38] found lower perfusion in the frontal lobes
and related subcortical structures in patients with AD who
manifested delusions and hallucinations. Taken together, this
research suggests that testosterone may interact with the
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currence of NPS.
There are a number of factors that limit the generalizability
of the results of the present study. The sample, although
drawn from a well-characterized AD cohort, is small, and
similar findings in much larger samples are needed to sup-
port our findings. Additionally, the study is cross-sectional
and as such assesses the relationship in mild to moderate
AD cases at one point in time. Longitudinal research is es-
pecially important in these patients, given the age-related
changes in testosterone that occur, as well as the changes
in the prevalence of the various NPS over time. The sam-
ple was overwhelmingly made up of non-Hispanic Cauca-
sians, which further limits the generalizability of the
results. TT may not be the best estimate of the level of
testosterone directly affecting the brain [39]. Importantly,
there was no control over the time of day when the sam-
ples were drawn, and testosterone levels are known to
fluctuate throughout the day. Additionally, data were not
available on the use of testosterone supplementation or
other medications that may have had an impact on testos-
terone levels. An additional limitation relates to the use of
informant data. The data on the presence of the NPS was
dependent on caregiver reports, and, although the data
were gathered by trained interviewers, the interpretation
of the symptoms may have varied from informant to in-
formant. Further research with larger samples studied
over the course of the disease will be useful to clarify the
relationship between testosterone and NPS in AD.
The findings of the present study are suggestive that
testosterone level may play a role in the occurrence of
“acting out” symptoms. As shown in earlier research on
testosterone and cognition [18,40], testosterone may
have detrimental rather than beneficial effects in certain
circumstances. It may be that once the disease pathology
has reached a certain point, whatever neuroprotective ef-
fects testosterone may have had no longer exist, and the
level of testosterone affects the likelihood of specific
negative behaviors.
There are a number of implications of our findings.
The strategy of using TRT to improve mood in hypo-
gonadal men with AD may have unintended conse-
quences, and therefore TRT should be used judiciously.
Assessing cognitive function may be necessary to aid in
determining whether to use TRT in older men who may
have unidentified prodromal AD. Additionally, measur-
ing testosterone in older men with AD may aid in identify-
ing individuals who have a greater likelihood of developing
NPS as the disease progresses.
Conclusions
This cross-sectional research on a sample of men with
mild to moderate AD found that the men with normal
levels of TT had significantly higher frequency of theNPSs of hallucinations, delusions, motor activity and
irritability than men classified as hypogonadal. These
findings, if supported by further research, have signifi-
cant implications for the use of TRT in AD and sug-
gest a mechanism by which to identify those at higher
risk for developing NPS.
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